Research Radar — 2026-07-01

Summary: Aerobic glycolysis, a hallmark of cancer, preferentially converts pyruvate into lactate. Guo et al. demonstrate that tumor aerobic glycolysis drives lactate production through PKM2-mediated phosphorylation and activation of LDHA. Lactate directly binds to and inhibits STING, and targeting PKM2 attenuates lactate-dependent immune evasion and synergizes with anti-PD-1 therapy.

Why it matters: Reveals a direct mechanistic link between cancer aerobic glycolysis and STING inhibition via lactate, identifying PKM2 as a druggable target to overcome lactate-driven immune evasion and improve checkpoint immunotherapy.

Why for Yiru: Directly relevant to Yiru's interest in tumor microenvironment and cancer immunology — this paper uncovers how metabolic byproducts suppress innate immune sensing, with clear therapeutic implications for combination immunotherapy.

Summary: In the phase 1 ReMIND trial of tumor-associated antigen-specific T cells in patients with pediatric central nervous system tumors, treatment was generally well tolerated with one complete response and three long-term responders.

Why it matters: First phase 1 trial of multi-antigen-targeting T cells in pediatric CNS tumors, demonstrating safety and durable responses — a pioneering step for cellular immunotherapy in hard-to-treat pediatric brain cancers.

Why for Yiru: Highly relevant to Yiru's interest in CAR-T and T cell immunotherapy — this multi-antigen targeting strategy addresses the antigen escape challenge that limits single-target CAR-T approaches in solid tumors.

Summary: Vascular RhoJ is identified as an effective and selective target for tumor angiogenesis and vascular disruption, offering a potential strategy for targeting tumor blood vessels with reduced off-tumor toxicity.

Why it matters: Identifies RhoJ as a tumor-selective vascular target for angiogenesis inhibition and vascular disruption, potentially overcoming the toxicity limitations of current anti-angiogenic therapies.

Why for Yiru: Relevant to Yiru's interest in tumor microenvironment — angiogenesis is a critical component of TME, and selective vascular targeting could complement immunotherapeutic approaches.

Summary: Nuclear receptor Nur77 is a transcription factor with immunomodulatory functions. By integrating patient-derived samples, organoid co-cultures, and mouse models of hepatocellular carcinoma, the authors show that Nur77 promotes NK cell maturation and cytotoxicity by reducing lipid-mediated suppression and upregulating AP-1 response genes. Nur77 agonism improves response to adoptive NK cell therapy in HCC preclinical models.

Why it matters: Identifies Nur77 as a druggable regulator of NK cell immunity in HCC, demonstrating that metabolic reprogramming via a nuclear receptor can enhance NK cell therapy — a new avenue for solid tumor immunotherapy beyond T cell-centric approaches.

Why for Yiru: Directly relevant to Yiru's interest in immunotherapy and tumor microenvironment — this work combines organoid co-cultures with in vivo models and opens NK cell-based therapeutic strategies for HCC, a cancer type with high unmet need.

Summary: Chronic hepatitis B is characterized by evolving host-virus engagement. Here the authors show that HBV-specific CD8 T cells lack features of terminal exhaustion seen in chronic HCV/HIV or cancer. Instead, emerging gene expression programs correlate with increasing HBV control, including a cytotoxic T-cell localization program and an NK-like T-cell program combining NK markers with cytotoxic genes.

Why it matters: Challenges the paradigm that chronic viral infection always drives T cell exhaustion — HBV-specific CD8 T cells maintain functional programs associated with viral control, with implications for immunotherapeutic design in chronic infections.

Why for Yiru: Relevant to Yiru's interest in T cell biology and transcriptomics — the discovery of NK-like cytotoxic programs in CD8 T cells may inform T cell engineering strategies for immunotherapy, and the single-cell transcriptomic approach is directly applicable.

Summary: The strength of T cell receptor engagement by antigenic ligands governs naive T cell activation, expansion and differentiation. Coupling an influenza infection model of varied TCR-ligand affinity with high-dimensional protein and RNA measurements reveals that TCR-ligand affinity primarily changes the magnitude of TCR-induced transcriptome remodelling, not the genes involved, with affinity-dependent amplification of ribosome biogenesis and suppression of interferon response genes.

Why it matters: Provides a quantitative framework for how TCR-ligand affinity tunes T cell responses in vivo, showing that affinity primarily modulates the magnitude rather than the program of transcriptome remodelling — fundamental insight for T cell engineering and vaccine design.

Why for Yiru: Relevant to Yiru's interest in T cell biology and computational immunology — understanding how TCR signal strength shapes T cell fate is important for designing more effective CAR-T and TCR-based therapies.